• 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 2
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335: 865875.
  • 3
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000; 163: 408417.
  • 4
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma.Groupe Francais d'Immunotherapie. N Engl J Med. 1998; 338: 12721278.
  • 5
    [No authors listed.] Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999; 353: 1417.
  • 6
    Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993; 260: 13171320.
  • 7
    Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7: 8590.
  • 8
    Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol. 1997; 17: 56295639.
  • 9
    Horstmann M, Merseburger AS, von der Heyde E, et al. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res Clin Oncol. 2005; 131: 715722.
  • 10
    Xu L, Tong R, Cochran DM, Jain RK. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005; 65: 57115719.
  • 11
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427434.
  • 12
    Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 1624.
  • 13
    Rini BI. Sorafenib. Expert Opin Pharmacother. 2006; 7: 453461.
  • 14
    Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol. 2005; 23: 53345346.
  • 15
    Li X, Liu X, Wang J, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 2003; 23: 24812487.
  • 16
    Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991; 173: 699703.
  • 17
    Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000; 82: 812817.
  • 18
    Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 302306.
  • 19
    Stebbing J, Benson C, Eisen T, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer. 2001; 85: 953958.
  • 20
    Mitsiades CS, Mitsiades N. CC-5013 (Celgene). Curr Opin Invest Drugs. 2004; 5: 635647.
  • 21
    Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005; 69: 5663.
  • 22
    Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999; 163: 380386.
  • 23
    Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003; 305: 12221232.
  • 24
    Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001; 98: 210216.
  • 25
    Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 106: 40504053.
  • 26
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549557.
  • 27
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 28
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 25302540.
  • 29
    Lee CP, Patel PM, Selby PJ, et al. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 898903.
  • 30
    Minor DR, Monroe D, Damico LA, Meng G, Suryadevara U, Elias L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs. 2002; 20: 389393.
  • 31
    Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol. 2002; 13: 10291035.
  • 32
    Daliani DD, Papandreou CN, Thall PF, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002; 95: 758765.
  • 33
    Gordon MS, Manola J, Fairclough D, et al. Low dose interferon-alpha 2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC): improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS) [abstract 4416]. Proc Am Soc Clin Oncol. 2004; 23: 384.
  • 34
    Rawat A, Needle MN, Miles B, Amato RJ. Phase II Study of CC-5013 in patients (pts) with metastatic renal cell cancer (MRCC) [abstract 4604]. Proc Am Soc Clin Oncol. 2005; 23: 403s.
  • 35
    Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002; 87: 11661172.
  • 36
    Dredge K, Marriott JB, Todryk SM, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol. 2002; 168: 49144919.
  • 37
    Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005; 65: 1171211720.
  • 38
    Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988; 318: 15571563.
  • 39
    Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993; 11: 13761383.
  • 40
    Strakosch CR, Wenzel BE, Row VV, Volpe R. Immunology of autoimmune thyroid diseases. N Engl J Med. 1982; 307: 14991507.
  • 41
    Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol. 1999; 17: 529533.
  • 42
    Laxmanan S, Robertson SW, Wang E, Lau JS, Briscoe DM, Mukhopadhyay D. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun. 2005; 334: 193198.
  • 43
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999; 5: 29632970.